Within the cord blood industry, there was a strong growth period during the 2000’s. However, over the past few years, the market has substantially matured and consolidated. While strong industry growth continues within North Asia (particularly China, Hong Kong, and Taiwan) and Southeast Asia (led by India and Malaysia), growth of the North American market is flat and the European cord blood banking market is declining. [Read more…]
This article identifies four key processing technologies that are utilized by cord blood banks worldwide and the companies responsible for developing each one.
Automated processing systems have many benefits, including speed, processing efficiency, and cost-savings.
However, automated processing systems have not always dominated the cord blood banking industry. [Read more…]
This article is a comparison of the top three largest U.S. cord blood banks:
The standard used to identify these cord blood banks was the number of cord blood and cord tissue units stored by each company.
The purpose of this analysis is to compare pricing and services among the largest cord blood banks within the U.S., the most mature cord blood banking market in the world. These three industry giants also represent several of the largest cord blood banks worldwide. [Read more…]
The cord blood processing method PrepaCyte-CB has been shown to engraft more quickly during the vital stage of post-transplant recovery than any other processing method. At the 15th Annual International Cord Blood Symposium in San Diego, California, in June 2017, the St. Louis Cord Blood Bank presented the median time it took patients infused with cord blood using either its Hetastarch or PrepaCyte-CB processing method to reach an absolute neutrophil count (ANC) of 500.
PrepaCyte-CB was found to engraft a full four days more quickly than the Hetastarch processing method (16 days versus 20 days) and has shown to be just as safe to the patient.1 Combining this data with those of other public data sources, PrepaCyte-CB was found to engraft more quickly than any other processing method. [Read more…]
Dr. Simantov brings to the company extensive medical experience in late stage development and commercialization of cancer treatments
Jerusalem, Israel and New York, New York, July 10, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Ronit Simantov, M.D. will join the Company as its new Chief Medical Officer (CMO) based in the U.S. [Read more…]